210 related articles for article (PubMed ID: 15637528)
1. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
3. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
4. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid.
Bittner B; Guenzi A; Fullhardt P; Zuercher G; González RC; Mountfield RJ
Arzneimittelforschung; 2002; 52(9):684-8. PubMed ID: 12404883
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.
Wempe MF; Wright C; Little JL; Lightner JW; Large SE; Caflisch GB; Buchanan CM; Rice PJ; Wacher VJ; Ruble KM; Edgar KJ
Int J Pharm; 2009 Mar; 370(1-2):93-102. PubMed ID: 19100824
[TBL] [Abstract][Full Text] [Related]
6. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
7. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
8. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.
Siegmund W; Ludwig K; Engel G; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Weitschies W
J Pharm Sci; 2003 Mar; 92(3):604-10. PubMed ID: 12587122
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
10. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.
Pathak SM; Udupa N
Biopharm Drug Dispos; 2010 Mar; 31(2-3):202-14. PubMed ID: 20238375
[TBL] [Abstract][Full Text] [Related]
13. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
14. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity.
Collnot EM; Baldes C; Wempe MF; Kappl R; Hüttermann J; Hyatt JA; Edgar KJ; Schaefer UF; Lehr CM
Mol Pharm; 2007; 4(3):465-74. PubMed ID: 17367162
[TBL] [Abstract][Full Text] [Related]
16. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté T; Oertel R; Terhaag B; Kirch W
Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
[TBL] [Abstract][Full Text] [Related]
17. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.
Shirasaka Y; Kuraoka E; Spahn-Langguth H; Nakanishi T; Langguth P; Tamai I
J Pharmacol Exp Ther; 2010 Jan; 332(1):181-9. PubMed ID: 19779132
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
[TBL] [Abstract][Full Text] [Related]
19. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
[TBL] [Abstract][Full Text] [Related]
20. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol.
Spahn-Langguth H; Langguth P
Eur J Pharm Sci; 2001 Feb; 12(4):361-7. PubMed ID: 11231102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
